β<sub>2</sub>-adrenoceptor agonists in asthma and COPD treatment

Małgorzata Kołaczkowska

ISSN: 1505-8409

Przewodnik Lekarza/Guide for GPs

Current issue Archive About the journal Supplements Contact Instructions for authors

2/2006
vol. 9

Send email

Copy url:

abstract:

β₂-adrenoceptor agonists in asthma and COPD treatment

Małgorzata Kołaczkowska

Przew Lek 2006: 2: 58-66

Online publish date: 2006/03/31

View full text Get citation

The basic symptom of asthma and COPD is bronchospasm, wchich is a result of chronic inflammation. In the treatment of airflow disturbances inhaled short- and long-acting β₂-agonists are adhibited in the first place. The effect of β₂-agonists therapeutic action is a result of β₂-adrenergic receptors distribution. Inhaled β₂-agonists differ in selectivity, receptor activation and the beginning and duration of activity. When combined with inhaled corticosteroids they improved lung function, and reduced symptoms and exacerbations more than an increased dose of corticosteroids. The most common side effects which occur during long-term treatment are: muscle tremor, tachycardia, hypoxemia and hypocaliemia (metabolic activity).

keywords:

β2-adrenoceptor agonists in asthma and COPD treatment

Małgorzata Kołaczkowska

asthma, COPD, β2-adrenoreceptor agonists

β₂-adrenoceptor agonists in asthma and COPD treatment

asthma, COPD, β₂-adrenoreceptor agonists